D-0470-2025 Class III Ongoing

Recalled by Macleods Pharmaceuticals Ltd — Mumbai

FDA drug recall D-0470-2025 was initiated by Macleods Pharmaceuticals Ltd on May 29, 2025 and is designated Class III. Reason for recall: Presence of a foreign substance: black hair found embedded in tablet. The recall status is ongoing. Affected quantity: 1,344- 1000 count bottles.

Recall details

Product Type
Drugs
Report Date
Jun 18, 2025
Initiation Date
May 29, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,344- 1000 count bottles

Product description

Levothyroxine Sodium Tablets, USP 112 mcg (0.112mg), 1000 tablets, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540. Manufactured by: Macleods Pharmaceuticals Ltd. Sarigam, Valsad, Gujarat, India, NDC 33342-398-44.

Reason for recall

Presence of a foreign substance: black hair found embedded in tablet.

Distribution pattern

Nationwide in the USA

Code information

Lot #: MLF2401A, Exp 01/31/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0470-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0470-2025. Report a data issue: hello@regdatalab.com.